|
|
| Nomenclature |
|
Symbol:
|
Tg(IghMyc)22Bri
|
|
Name:
|
transgene insertion 22, Ralph L Brinster
|
|
MGI ID: |
MGI:2447604 |
|
Synonyms: |
Emu-c-myc, Emu-cmyc Tg, Emu-myc, Tg-IghMyc-22Bri |
|
Transgene:
|
Tg(IghMyc)22Bri
Location:
unknown
|
|
Transgene
origin |
|
Strain of Origin:
|
(C57BL x SJL)F2
|
|
Transgene
description |
|
Transgene
Type: | |
Transgenic (random, expressed) |
|
Mutation: | |
Insertion |
| |
|
Mutation details: Expression of the mouse Myc transgene is directed to the B cell lineage by the Igh (E mu) enhancer and Myc promoter. The transgene was originally designated E-Myc. (J:78177)
|
|
Phenotypes
|
View phenotypes for all genotypes (concatenated display).
|
|
Disease models
|
|
| Find Mice (IMSR) |
Mouse strains and cell lines available from the
International Mouse Strain Resource
(IMSR)
|
|
Notes |
13 out of 15 transgenic founders developed lymphomas between 6 and 15 weeks of age. The animals became terminally ill and died or were sacrificed.
Hemizygous mice on a C57BL/6 background display increased pre-B cells in the bone marrow throughout life and a transient increase in large pre-B cells in the blood at 3-4 weeks of age. Spontaneous pre-B and B cell lymphomas reach an incidence of 50% at 15-20 weeks in hemizygous progeny of a wildtype female mated with a hemizygous male.
In conjuction with Tg(BCL2)22Wehi, transgenic mice on a C57BL/6 background exhibit the production of primitive lymphoid tumors within 5 weeks of birth
|
| References |
|
Original: |
J:78177
Adams JM et al.,
"The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice."
Nature 1985 Dec 12-18;318(6046):533-8
|
|
All: |
138 reference(s)
|
|
Analysis Tools
